Hospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (43)

2024

  1. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

    npj Breast Cancer, Vol. 10, Núm. 1

  2. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

  3. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

2023

  1. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

  2. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

    Nature Communications, Vol. 14, Núm. 1

  3. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

    Frontiers in Oncology, Vol. 13

  4. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

    Annals of Oncology, Vol. 34, Núm. 8, pp. 670-680

  5. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

    ESMO Open, Vol. 8, Núm. 3

  6. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

2022

  1. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis

    Cancer Treatment Reviews, Vol. 104

  2. Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 5, pp. 93-1003

  3. Gene expression profiles of breast cancer metastasis according to organ site

    Molecular Oncology, Vol. 16, Núm. 1, pp. 69-87

  4. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  5. Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

    European Journal of Cancer, Vol. 174, pp. 232-242

2021

  1. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 489-498

  2. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  3. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

    npj Breast Cancer, Vol. 7, Núm. 1

  4. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

    Frontiers in Oncology, Vol. 11

  5. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

    EBioMedicine, Vol. 69

  6. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499